Yes, Triumeq Can Cause Hypersensitivity Reactions
Triumeq (dolutegravir/abacavir/lamivudine) carries a boxed warning for hypersensitivity reactions, primarily linked to its abacavir component. These reactions occur in about 5-8% of patients and can be life-threatening if not addressed promptly.[1][2]
Symptoms to Watch For
Reactions typically appear within the first 6 weeks of starting treatment. Common signs include:
- Fever
- Rash (often severe)
- Fatigue
- Nausea, vomiting, or diarrhea
- Cough or shortness of breath
- Muscle or joint pain
Severe cases may involve liver damage, low blood pressure, or throat swelling. Stop the drug immediately and seek emergency care if any symptoms emerge—do not rechallenge with abacavir.[1][3]
Who Is at Higher Risk?
Patients testing positive for the HLA-B*5701 allele face up to 50% risk of reaction. Screening for this genetic marker is standard before prescribing Triumeq to avoid it entirely in high-risk individuals.[1][2] Risk is unrelated to CD4 count or HIV stage, though women and those with autoimmune conditions report it slightly more often.[3]
What Happens If It Occurs?
Discontinue Triumeq permanently. Most symptoms resolve within days to weeks after stopping, but fatal outcomes have occurred from continued use or rechallenge. Switch to alternatives like dolutegravir/lamivudine (without abacavir) or bictegravir-based regimens.[1][4]
Testing and Prevention Steps
HLA-B*5701 screening is required by FDA labeling. A negative test does not eliminate risk (reactions occur in ~3% of negatives), so monitor closely for 6 weeks. Carry a warning card listing symptoms.[1][2]
Comparison to Similar Drugs
Unlike Tivicay (dolutegravir alone), which rarely causes hypersensitivity (~1%), Triumeq's abacavir drives the higher rate. Epzicom (abacavir/lamivudine) shares this risk profile.[3][4]
[1]: Triumeq Prescribing Information (FDA)
[2]: Drugs.com - Triumeq Side Effects
[3]: Medscape - Triumeq Warnings
[4]: NIH HIV Guidelines - ART Reactions